Advertisement

Drugs & Therapy Perspectives

, Volume 34, Issue 10, pp 472–476 | Cite as

If necessary, use antiarrhythmic drugs to treat acute and chronic supraventricular tachycardia in infants

  • Adis Medical Writers
Disease Management
  • 38 Downloads

Abstract

Supraventricular tachycardia (SVT) is the most common arrhythmia in infants. Older children and adults with SVT are commonly managed with catheter ablation of the SVT substrate; however, such treatment is the last resort in infants because the risks of the procedure outweigh its benefits and most SVTs in infants resolve spontaneously in the first year of life. SVT in infants is generally managed with electrical cardioversion, vagal manoeuvres and antiarrhythmic drugs (e.g. adenosine, esmolol and procainamide as acute therapy, and digoxin and class Ic, II or III antiarrhythmics, most commonly propranolol, as chronic therapy).

Notes

Compliance with ethical standards

Conflict of interest

The article was adapted from Pediatric Drugs 2017;19(6):539–51 [2] by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest.

Funding

The preparation of this review was not supported by any external funding.

References

  1. 1.
  2. 2.
    Richardson C, Silver ES. Management of supraventricular tachycardia in infants. Pediatr Drugs. 2017;19(6):539–51.CrossRefGoogle Scholar
  3. 3.
    Salerno JC, Seslar SP. Supraventricular tachycardia. Arch Pediatr Adolesc Med. 2009;163(3):268–74.CrossRefGoogle Scholar
  4. 4.
    Chu PY, Hill KD, Clark RH, et al. Treatment of supraventricular tachycardia in infants: analysis of a large multicenter database. Early Hum Dev. 2015;91(6):345–50.CrossRefGoogle Scholar
  5. 5.
    Patti L, Gossman WG. Rhythm, tachycardia, supraventricular (SVT). Treasure Island: StatPearls Publishing. 2017. https://www.ncbi.nlm.nih.gov/books/NBK441972/. Accessed 17 May 2018.
  6. 6.
    Fenrich AL Jr, Perry JC, Friedman RA. Flecainide and amiodarone: combined therapy for refractory tachyarrhythmias in infancy. J Am Coll Cardiol. 1995;25(5):1195–8.CrossRefGoogle Scholar
  7. 7.
    Price JF, Kertesz NJ, Snyder CS, et al. Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children < 1 year of age. J Am Coll Cardiol. 2002;39(3):517–20.CrossRefGoogle Scholar
  8. 8.
    Garson A Jr, Moak JP, Smith RT Jr, et al. Usefulness of intravenous propafenone for control of postoperative junctional ectopic tachycardia. Am J Cardiol. 1987;59(15):1422–4.CrossRefGoogle Scholar
  9. 9.
    Reimer A, Paul T, Kallfelz HC. Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias. Am J Cardiol. 1991;68(8):741–4.CrossRefGoogle Scholar
  10. 10.
    Janousek J, Paul T. Safety of oral propafenone in the treatment of arrhythmias in infants and children (European retrospective multicenter study). Am J Cardiol. 1998;81(9):1121–4.CrossRefGoogle Scholar
  11. 11.
    Betapace/Betapace AF (sotalol hydrochloride) tablets: US prescribing information. Zug, Switzerland: Covis Pharma: 2016.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations